Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Body composition dynamics, pharmacokinetics, and toxicity of nab-paclitaxel in patients with malignant tumors in northern China
ChiCTR2300078985Phase 4Completed
- Sponsor
- Ordos Central Hospital
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of paclitaxel in cancer (2 arms), sponsored by Ordos Central Hospital. Primary endpoints: Skeletal muscle index, Lean body mass and 2 more. Started Dec 2023; status: completed.
02
Drugs
paclitaxel
03
Conditions
cancer
Beyond the preview
Go deeper on ChiCTR2300078985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078985.